Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859727 · ClinicalTrials.gov registry record · Phase 2
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
A Phase 2 study, sponsored by Pharming Technologies B.V..
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02859727 is a Phase 2 study that was terminated before completion, run by Pharming Technologies B.V.. The registered enrollment target is 37 participants.
The verdict
NCT02859727, a Phase 2 study, was terminated before completion, sponsored by Pharming Technologies B.V..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were treated previously with PI3Kδ inhibitors other than CDZ173. The study is open-label designed to establish the long-term safety, tolerability, efficay and pharmacokinetics of CDZ173 in the target population.
Interventions
- DRUG CDZ173
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-09-08 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859727
The ClinicalTrials.gov registry entry for NCT02859727 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharming Technologies B.V., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDZ173 is the first listed.
NCT02859727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859727 about?
NCT02859727 is a clinical study titled "Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI". This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were treated previously with PI3Kδ inhibitors other than CDZ173. The study is ...
What is the current status of trial NCT02859727?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2016-09-08. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT02859727?
The interventions under investigation include: CDZ173 (DRUG).
Who is sponsoring clinical trial NCT02859727?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.